<DOC>
	<DOCNO>NCT01647880</DOCNO>
	<brief_summary>In MOVING study examine , whether early therapeutic intervention fingolimod ( Gilenya ® ) optic neuritis ( ON ) favorable visual outcome comparative therapie Interferon beta-1b ( Extavia® ) , measure multifocal visual evoke potential ( mVEP ) 6 month compare baseline .</brief_summary>
	<brief_title>MOdification VIsual Outcomes After Optic Neuritis CIS MS Gilenya ( MOVING Study )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Diagnosis relapsingremitting multiple sclerosis ( RRMS ) ability consent write approval First acute ON attack fit eye within 30 day screen Age 18 55 year screen EDSS ≤ 6.0 No MS Attack except ON last 30 day screen No immunomodulatory therapy least three Months ( randomization ) , strong immunomodulatory therapy interferon beta glatiramer acetate least 6 month visus affect eye least 0.1 latency Conventional VEP affect eye = 115 m difference &gt; = 15 m opposite side Study least 4 6 week Onset clinical symptom At least 2 T2 lesion typical MS previous MRI MS course RRMS condition could interfere prevent MRI study investigation know allergy intolerance , contraindication GdDTPA Patients known contraindication treatment fingolimod ( Gilenya ® ) interferon beta1b Extavia ® Competing disease could affect visual function diabetic , retinopathy , glaucoma , retinal detachment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>